/*
* Concept profile generation tool suite
* Copyright (C) 2015 Biosemantics Group, Erasmus University Medical Center,
* Rotterdam, The Netherlands
*
* This program is free software: you can redistribute it and/or modify
* it under the terms of the GNU Affero General Public License as published
* by the Free Software Foundation, either version 3 of the License, or
* (at your option) any later version.
*
* This program is distributed in the hope that it will be useful,
* but WITHOUT ANY WARRANTY; without even the implied warranty of
* MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the
* GNU Affero General Public License for more details.
*
* You should have received a copy of the GNU Affero General Public License
* along with this program. If not, see <http://www.gnu.org/licenses/>
*/
package org.erasmusmc.rmi.peregrine.client;
import java.util.List;
import org.erasmusmc.peregrine.ResultConcept;
public class RMIPeregrineTest {
public static void main(String[] args) throws Exception {
//RMIPeregrine peregrine = new RMIPeregrine("kristina.erasmusmc.nl", 111, "RMIPeregrineServerService");
RMIPeregrine peregrine = new RMIPeregrine("mojojojo.biosemantics.org", 1011, "RMIPeregrineServerService");
peregrine.setDisambiguate(false);
//peregrine.setDisambiguate(true);
for(int i=0; i<10000;i++) {
peregrine.index("PURPOSE: The aim of this study was to evaluate the feasibility and safety of salvage high-d" +
"ose-rate (HDR) brachytherapy for locally recurrent prostate cancer after external beam radiotherapy (EBRT). " +
"METHODS AND MATERIALS: We retrospectively analyzed 21 consecutively accrued patients undergoing salvage HDR " +
"brachytherapy for locally recurrent prostate cancer after EBRT between November 1998 and December 2005. After" +
" pathologic confirmation of locally recurrent disease, all patients were treated with 36 Gy in six fractions" +
" using two transrectal ultrasound-guided HDR prostate implants, separated by 1 week. Eleven patients received " +
"neoadjuvant hormonal therapy immediately presalvage, whereas none received adjuvant hormonal therapy postsalvage." +
" Median follow-up time from recurrence was 18.7 months (range, 6-84 months). Determination of subsequent biochemical " +
"failure after brachytherapy was based on the definition by the American Society for Therapeutic Radiology and Oncology." +
" RESULTS: Based on the Common Terminology Criteria for Adverse Events (CTCAE version 3), 18 patients reported Grade 1 to 2" +
" genitourinary symptoms by 3 months postsalvage. Three patients developed Grade 3 genitourinary toxicity. Maximum observed" +
" gastrointestinal toxicity was Grade 2; all cases spontaneously resolved. The 2-year Kaplan-Meier estimate of biochemical" +
" control after recurrence was 89%. Thirteen patients have achieved a PSA nadir </=0.1 ng/ml, but at the time of writing this" +
" endpoint has not yet been reached for all patients. All patients are alive; however 2 have experienced biochemical failure, " +
"both with PSA nadirs >/=1, and have subsequently been found to have distant metastases. CONCLUSIONS: Salvage HDR prostate " +
"brachytherapy appears to be feasible and effective.");
List<ResultConcept> resultConcepts = peregrine.resultConcepts;
if (i % 100 == 0){
for(ResultConcept result: resultConcepts) {
System.out.println(result.conceptId);
}
System.out.println("***"+i);
/*for(ResultTerm result: resultTerms) {
System.out.println(result.term.termId);
for(String str :tokenizer.tokens) {
System.out.println(str);
}
}*/
}
}
}
}